The global transplant diagnostics size was estimated to be USD 4.5 billion in 2023 and is expected to reach at USD 10.3 billion by 2033 with a CAGR of 7.8% during the forecast period 2023-2033. Increasing organ transplantations, advancements in transplantation techniques, growing awareness and supportive regulations, technological advancements in diagnostics, and growing transplant tourism will drive the market growth.
The scope and success rates of organ transplantation have increased thanks to technological developments such as enhanced surgical techniques, tissue engineering, and regenerative medicine. In order to find potential donors, reduce the chance of rejection, and improve transplant outcomes, transplant diagnostics are essential. For instance, Hologic announced in September 2021 that the FDA had approved their Panther Fusion GBS (Group B Streptococcus) assay, a test used to identify GBS colonisation in pregnant women. This test may be useful in transplant diagnostics to check for GBS in both donors and recipients.
By product type, reagents and consumables was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to its essential role in conducting a wide range of diagnostic tests and the consistent demand for reagents and consumables in transplant diagnostics procedures. For instance, Thermo Fisher Scientific announced the release of its Ion Torrent Genexus System, a next-generation sequencing platform, in September 2021. This system allows automated sample preparation and data processing for quicker and more effective genetic testing, including transplant diagnostics. Services and software will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the increasing adoption of digital solutions and the need for comprehensive transplant diagnostic services.
By technology, molecular assays was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the increased adoption of DNA-based testing methods and their crucial role in accurate tissue typing and genetic matching for successful organ transplantation. For instance, in January 2021, Illumina revealed that it had acquired GRAIL, a healthcare business that specialises in early detection diagnostics for several cancers. The field of liquid biopsy, which has applications in transplant diagnostics, is strengthened by this acquisition for Illumina. Non-molecular assays will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to its ability to provide highly accurate and comprehensive genetic information for precise tissue typing and personalized transplant management.
By end-user, hospitals and transplant centers was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to their central role as primary providers of transplant services and the increasing number of organ transplant procedures performed in these settings. For instance, Bio-Rad Laboratories introduced the IH-Reader 24, a completely automated blood type and antibody screening device, in March 2021. The device offers accurate and effective blood compatibility testing during transplant procedures. Research institutes and academic centers will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the expanding scope of research and development activities in transplant diagnostics and the growing collaborations between academia and industry.
The scope and success rates of organ transplantation have increased thanks to technological developments such as enhanced surgical techniques, tissue engineering, and regenerative medicine. In order to find potential donors, reduce the chance of rejection, and improve transplant outcomes, transplant diagnostics are essential. For instance, Hologic announced in September 2021 that the FDA had approved their Panther Fusion GBS (Group B Streptococcus) assay, a test used to identify GBS colonisation in pregnant women. This test may be useful in transplant diagnostics to check for GBS in both donors and recipients.
By product type, reagents and consumables was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to its essential role in conducting a wide range of diagnostic tests and the consistent demand for reagents and consumables in transplant diagnostics procedures. For instance, Thermo Fisher Scientific announced the release of its Ion Torrent Genexus System, a next-generation sequencing platform, in September 2021. This system allows automated sample preparation and data processing for quicker and more effective genetic testing, including transplant diagnostics. Services and software will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the increasing adoption of digital solutions and the need for comprehensive transplant diagnostic services.
By technology, molecular assays was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the increased adoption of DNA-based testing methods and their crucial role in accurate tissue typing and genetic matching for successful organ transplantation. For instance, in January 2021, Illumina revealed that it had acquired GRAIL, a healthcare business that specialises in early detection diagnostics for several cancers. The field of liquid biopsy, which has applications in transplant diagnostics, is strengthened by this acquisition for Illumina. Non-molecular assays will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to its ability to provide highly accurate and comprehensive genetic information for precise tissue typing and personalized transplant management.
By end-user, hospitals and transplant centers was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to their central role as primary providers of transplant services and the increasing number of organ transplant procedures performed in these settings. For instance, Bio-Rad Laboratories introduced the IH-Reader 24, a completely automated blood type and antibody screening device, in March 2021. The device offers accurate and effective blood compatibility testing during transplant procedures. Research institutes and academic centers will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the expanding scope of research and development activities in transplant diagnostics and the growing collaborations between academia and industry.
Global Transplant Diagnostics, By Region (USD Billion)
North America was the highest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to its advanced healthcare infrastructure, increasing prevalence of chronic diseases, high adoption rate of technologically advanced diagnostic solutions, and strong support from government initiatives. For instance, QIAGEN announced the expansion of its QuantiFERON-TB Access Programme in July 2021 to offer greater access to tuberculosis (TB) testing in low-resource areas, including locations where transplant diagnostics are essential for TB screening in donors and recipients. Asia Pacific will be the fastest revenue-grossing segment in the global transplant diagnostics market in 2022 owing to the increasing prevalence of chronic diseases, a rising demand for organ transplants, improving healthcare infrastructure, and a growing focus on improving transplant outcomes in the region.Global Molecular Assays Market (USD Billion), 2023 & 2033
This comprehensive research report focuses on the global and regional market size and forecasts from 2022 to 2033.Report Scope:
- Base Year: 2022
- Forecast Period: 2023-2033
- Study Coverage
- Market Forecast by Product type, Technology, End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Transplant Diagnostics Market Report 2022-2033
Transplant Diagnostics Market Analysis & Forecast by Product Type 2022-2033 (Revenue USD Bn)
- Reagents & Consumables
- Instruments
- Software and Services
Transplant Diagnostics Market Analysis & Forecast by Technology 2022-2033 (Revenue USD Bn)
- Serological Assays
- Molecular Assays
- Non-Molecular Assays
Transplant Diagnostics Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Bn)
- Hospitals and Transplant Centers
- Research Institutes and Academic Centers
Transplant Diagnostics Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin American
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Transplant Diagnostics: Product Type Estimates & Trend Analysis
8. Transplant Diagnostics: Technology Estimates & Trend Analysis
9. Transplant Diagnostics: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Western Blotting Market
12. Europe Global Western Blotting Market
13. Asia Pacific Global Western Blotting Market
14. Latin America Global Western Blotting Market
15. MEA Global Western Blotting Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Biomérieux SA
- F Hoffmann La Roche AG
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Immucor, Inc.
- Biocartis
- Ophiomics
- NephroSant
- Natera Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 4.5 Billion |
| Forecasted Market Value ( USD | $ 10.3 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
